Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Greece
Hormone receptor
Human epidermal growth factor receptor 2
Metastatic breast cancer
Overall survival
Progression-free survival
Treatment patterns
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Jan 2019
18 Jan 2019
Historique:
received:
19
12
2017
accepted:
10
01
2019
entrez:
20
1
2019
pubmed:
20
1
2019
medline:
30
4
2019
Statut:
epublish
Résumé
The "EMERGE" study, aimed to capture real-life management patterns and outcomes in metastatic breast cancer (MBC) in Greece, also accounting for hormone (HR) and human epidermal growth factor receptor 2 (HER2) status. "EMERGE" was a multicenter, retrospective cohort study of adult MBC patients diagnosed between 01-Janaury-2010 and 30-June-2012, either de novo or having progressed from a non-metastatic state. Patient data, including treatment patterns and outcomes, were mainly abstracted through medical chart review. 386 patients were enrolled by 16 hospital-based oncologists between 12-March-2013 and 31-March-2015. The median look-back period was 29.1 months. At MBC diagnosis, 56.1% of the patients were HR "EMERGE" demonstrates differences between HR/HER2 subtypes in clinical outcomes and divergence from evidence-based guideline recommendations for MBC management, especially as it pertains to the HR The study has been registered on the electronic Registry of Non-Interventional Studies (RNIS) posted on the website of the Hellenic Association of Pharmaceutical Companies (SFEE): https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=NIS-OGR-XXX-2012/1.
Sections du résumé
BACKGROUND
BACKGROUND
The "EMERGE" study, aimed to capture real-life management patterns and outcomes in metastatic breast cancer (MBC) in Greece, also accounting for hormone (HR) and human epidermal growth factor receptor 2 (HER2) status.
METHODS
METHODS
"EMERGE" was a multicenter, retrospective cohort study of adult MBC patients diagnosed between 01-Janaury-2010 and 30-June-2012, either de novo or having progressed from a non-metastatic state. Patient data, including treatment patterns and outcomes, were mainly abstracted through medical chart review.
RESULTS
RESULTS
386 patients were enrolled by 16 hospital-based oncologists between 12-March-2013 and 31-March-2015. The median look-back period was 29.1 months. At MBC diagnosis, 56.1% of the patients were HR
CONCLUSIONS
CONCLUSIONS
"EMERGE" demonstrates differences between HR/HER2 subtypes in clinical outcomes and divergence from evidence-based guideline recommendations for MBC management, especially as it pertains to the HR
STUDY REGISTRATION
BACKGROUND
The study has been registered on the electronic Registry of Non-Interventional Studies (RNIS) posted on the website of the Hellenic Association of Pharmaceutical Companies (SFEE): https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=NIS-OGR-XXX-2012/1.
Identifiants
pubmed: 30658600
doi: 10.1186/s12885-019-5301-5
pii: 10.1186/s12885-019-5301-5
pmc: PMC6339387
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Références
Breast Cancer Res Treat. 2006 Jun;97(3):237-44
pubmed: 16322882
Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47
pubmed: 18243010
Cancer Res. 2009 Jun 15;69(12):4951-3
pubmed: 19470768
Breast Cancer Res Treat. 2010 Feb;119(3):621-31
pubmed: 19915976
Ann Oncol. 2010 Nov;21(11):2169-74
pubmed: 20427349
J Clin Oncol. 2011 Feb 1;29(4):456-63
pubmed: 21189397
Breast Cancer. 2012 Jul;19(3):191-9
pubmed: 21567170
Anticancer Drugs. 2011 Oct;22(9):933-9
pubmed: 21666437
Breast Cancer Res. 2011 Jun 27;13(3):212
pubmed: 21787441
Clin Breast Cancer. 2013 Apr;13(2):88-94
pubmed: 23218473
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Breast Care (Basel). 2013 Aug;8(4):256-62
pubmed: 24415978
Curr Med Res Opin. 2014 Aug;30(8):1537-45
pubmed: 24669852
J Natl Cancer Inst. 2014 Apr 28;106(5):null
pubmed: 24777111
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
Breast Cancer Res Treat. 2014 Jun;145(3):615-23
pubmed: 24820412
J Cancer Epidemiol. 2014;2014:469251
pubmed: 24955090
Br J Cancer. 2015 Apr 28;112(9):1445-51
pubmed: 25880008
Ann Oncol. 2016 Feb;27(2):256-62
pubmed: 26578730
Onco Targets Ther. 2015 Nov 11;8:3337-48
pubmed: 26648738
Oncologist. 2016 Sep;21(9):1050-62
pubmed: 27401886
BMC Cancer. 2016 Sep 15;16(1):734
pubmed: 27634735
Cancer Treat Rev. 2017 Jan;52:33-40
pubmed: 27886589
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Ann Oncol. 2017 Jan 1;28(1):16-33
pubmed: 28177437